01 Growing Adoption of Real-World Data and AI-Enabled Evidence Generation The Real World Evidence (RWE) Solutions Market is being driven by increasing demand for real-world data to support healthcare decision-making, clinical research, regulatory submissions, and value-based care. Pharmaceutical companies, healthcare providers, and payers are increasingly using electronic health records, claims databases, patient registries, pharmacy data, and digital health platforms to generate evidence on treatment effectiveness, safety, and outcomes in routine clinical settings. Advances in artificial intelligence (AI), machine learning, natural language processing, and advanced analytics are helping organizations process large and complex datasets and identify clinically meaningful insights more efficiently. The RWE Market is also expanding as regulators and health technology assessment organizations place greater emphasis on evidence generated from real-world clinical practice. In addition, growing adoption of decentralized trials, patient-generated data, and connected healthcare technologies is creating new sources of real-world information. Improved data interoperability, privacy controls, and cloud-based analytics platforms are further supporting the development of scalable RWE solutions across the pharmaceutical and healthcare industries. In January 2025, the U.S. Food and Drug Administration released draft guidance on using real-world data and real-world evidence to support regulatory decision-making for drugs and biological products, further clarifying expectations for data relevance, reliability, and study design.
01 Growing Demand for Evidence-Based Healthcare and Increasing Use of Real-World Data in Drug Development Demand is supported by the increasing use of real-world data from electronic health records, insurance claims, patient registries, pharmacy databases, and other healthcare sources to evaluate treatment safety, effectiveness, utilization, and outcomes outside traditional clinical trials. Pharmaceutical and medical device companies are increasingly using real-world evidence to support regulatory submissions, post-market surveillance, health economics and outcomes research, market access, and lifecycle management. Growing healthcare costs and the shift toward value-based care are also encouraging payers and providers to assess the real-world performance and economic value of therapies. Advances in artificial intelligence, data integration, cloud computing, and analytics are making it easier to process large and diverse healthcare datasets, supporting broader adoption across the Real World Evidence (RWE) Solutions Market.
01 Data Quality Issues and Complex Integration of Fragmented Healthcare Information The market faces challenges because real-world data is generated across fragmented healthcare systems with differences in structure, coding standards, completeness, accuracy, and accessibility. Electronic health records, claims databases, registries, pharmacy records, and patient-generated data may use inconsistent formats, making data harmonization and integration complex. Missing information, duplicated records, inconsistent clinical terminology, and differences in patient populations can affect the reliability and comparability of evidence. Organizations must also invest in specialized data scientists, epidemiologists, statisticians, and technology infrastructure to transform raw data into regulatory-grade evidence. These requirements can increase implementation costs and extend project timelines, particularly for smaller pharmaceutical companies, healthcare organizations, and research institutions with limited analytics capabilities.
01 Expansion of AI-Powered Analytics and Regulatory Acceptance of Real-World Evidence The RWE Market is expected to benefit from increasing regulatory acceptance of real-world evidence and the growing integration of artificial intelligence, machine learning, predictive analytics, and automated data processing. AI can help organizations identify patient cohorts, analyze longitudinal treatment patterns, detect safety signals, and generate insights from large volumes of unstructured clinical information. Growing adoption of decentralized trials and hybrid clinical research models is also creating opportunities to combine traditional trial data with real-world information, improving patient diversity and long-term outcome assessment. These developments are expected to strengthen the market by improving the speed, scale, and efficiency of healthcare evidence generation.
01 Ensuring Regulatory-Grade Evidence, Data Privacy, and Cross-System Interoperability Real-world evidence providers must address challenges related to data privacy, cybersecurity, regulatory acceptance, interoperability, methodological consistency, and the ability to demonstrate that findings are reliable and representative. Healthcare data often contains sensitive patient information and must be processed under strict privacy and security requirements, while organizations operating across multiple countries must comply with different data protection and healthcare regulations. Researchers must also account for treatment-selection bias, missing data, differences in patient populations, and other methodological limitations when generating evidence from observational datasets. Integrating information across hospitals, insurers, pharmacies, registries, and digital health platforms can further complicate evidence generation. These challenges require robust governance frameworks, advanced analytics, standardized methodologies, secure data environments, and transparent validation processes to ensure that real-world evidence can support high-stakes clinical, regulatory, and reimbursement decisions.
March 2026 IQVIA expanded its real-world evidence (RWE) capabilities with enhanced AI-powered analytics and healthcare data solutions, enabling pharmaceutical companies to generate insights from real-world clinical and patient data for drug development and commercialization decisions.
January 2026 Oracle Health expanded its real-world data and analytics solutions with improved cloud-based healthcare data management capabilities, supporting life sciences organizations in evidence generation, clinical research, and regulatory submissions.
October 2025 ICON expanded its real-world evidence services portfolio with advanced data analytics and evidence-generation solutions, helping biopharmaceutical companies evaluate treatment effectiveness and healthcare outcomes beyond clinical trials.
August 2025 Parexel expanded its real-world evidence and late-phase research capabilities with enhanced data analytics platforms and observational study solutions to support evidence-based decision-making for healthcare organizations.